Efficacy evaluation of minimally invasive particle implantation in treating head and neck malignancies under different guidance methods: a propensity score matching analysis study [PDF]
Qing Yan, Xin Li
openalex +1 more source
ABSTRACT Objective To compare the effectiveness and safety of tenecteplase (TNK) versus alteplase (TPA) in patients with basilar artery occlusion prior to endovascular treatment (EVT). Methods In this retrospective multicenter study (BAO‐TNK), we analyzed consecutive BAO patients from 14 U.S.
Rahul R. Karamchandani +38 more
wiley +1 more source
A combined genomic arrhythmia propensity score delineates cumulative risk. [PDF]
Monroe TO +14 more
europepmc +1 more source
Adjusting for unobserved confounding using large-scale propensity scores [PDF]
Linying Zhang +4 more
openalex
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Psychotropic medication use and risks of kidney injury and fall-related events: a propensity score-matched cohort study. [PDF]
Wu YH, Tsai SF, Huang SS, Hou PH.
europepmc +1 more source
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai +28 more
wiley +1 more source
Propensity Score Matching in Non-Interventional Studies: A Step-by-Step Guide for Clinicians and Researchers. [PDF]
Pourahmad S, Madadizadeh F.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
A Tutorial for Propensity Score Weighting Methods Under Violations of the Positivity Assumption. [PDF]
Liu Y +4 more
europepmc +1 more source

